{'52WeekChange': 0.6766776,
 'SandP52WeekChange': None,
 'address1': 'Sydmarken  11',
 'address2': 'SOeborg',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 35.44,
 'askSize': 800,
 'averageDailyVolume10Day': 3462,
 'averageVolume': 5603,
 'averageVolume10days': 3462,
 'beta': 1.073837,
 'beta3Year': None,
 'bid': 35,
 'bidSize': 800,
 'bookValue': 6.321,
 'category': None,
 'circulatingSupply': None,
 'city': 'Copenhagen',
 'companyOfficers': [],
 'country': 'Denmark',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 35.41,
 'dayLow': 35.165,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1294906368,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '45 88 77 38 98',
 'fiftyDayAverage': 36.417713,
 'fiftyTwoWeekHigh': 44.6,
 'fiftyTwoWeekLow': 18.75,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 28341751,
 'forwardEps': -3.24,
 'forwardPE': -10.929012,
 'fromCurrency': None,
 'fullTimeEmployees': 191,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.07597,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/zealandpharma.com',
 'longBusinessSummary': 'Zealand Pharma A/S, a biotechnology company, engages '
                        'in the discovery and development of peptide-based '
                        'medicines in Denmark. It has a portfolio of medicines '
                        'in development stage focusing on gastrointestinal and '
                        'metabolic diseases. The company markets lixisenatide '
                        'under the brand names of Adlyxin, Lyxumia, Soliqua '
                        '100/33, and Suliqua. Its product pipeline includes '
                        'glepaglutide, a long acting GLP-2 analog, which is in '
                        'Phase 3 clinical trials for the treatment of short '
                        'bowel syndrome; and dasiglucagon, a stable glucagon '
                        'analog for the treatment of severe hypoglycemia in '
                        'diabetes and congenital hyperinsulinism, as well as '
                        'for use in dual-hormone artificial pancreas for '
                        'automated diabetes management. Zealand Pharma A/S has '
                        'collaboration agreements with Sanofi-Aventis '
                        'Deutschland GmbH; Boehringer Ingelheim International '
                        'GmbH; and Beta Bionics, Inc. to initiate home-use '
                        'trial of the iLet bionic pancreas with dasiglucagon '
                        'for autonomous bihormonal treatment of type 1 '
                        'diabetes, as well as research agreement with Orbit '
                        'Discovery Ltd. and Torrey Pines Institute for '
                        'Molecular Studies. The company was founded in 1997 '
                        'and is headquartered in Copenhagen, Denmark.',
 'longName': 'Zealand Pharma A/S',
 'market': 'us_market',
 'marketCap': 1418637952,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_1268514',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 35.23,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '45 88 77 36 00',
 'previousClose': 35.73,
 'priceHint': 2,
 'priceToBook': 5.6019616,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 35.41,
 'regularMarketDayLow': 35.165,
 'regularMarketOpen': 35.23,
 'regularMarketPreviousClose': 35.73,
 'regularMarketPrice': 35.23,
 'regularMarketVolume': 959,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 39669900,
 'sharesPercentSharesOut': 0.0019,
 'sharesShort': 77017,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 80197,
 'shortName': 'Zealand Pharma A/S',
 'shortPercentOfFloat': None,
 'shortRatio': 11.46,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ZEAL',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 3.002,
 'trailingPE': 11.795469,
 'twoHundredDayAverage': 35.28449,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '010b5b91-86dc-356a-bdf9-a4405de7b746',
 'volume': 959,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.zealandpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '2860'}